Targeting the p160 Steroid Receptor Coactivators (SRCs) as a Novel Approach for the Treatment of Castration-Resistant Prostate Cancer
About Targeting the p160 Steroid Receptor Coactivators (SRCs) as a Novel Approach for the Treatment of Castration-Resistant Prostate Cancer
What this means to patients: This study holds potential to identify a new class of potent inhibitors of CRPC development and treatment resistance to new drugs such as Zytiga (abiraterone) and Enzalutamide (MDV3100).
Synopsis: Androgen receptor (AR) signaling remains a key driver of prostate cancer growth and treatment resistance—highlighting the need for additional approaches to blocking AR signaling after complete androgen depletion with current medications. Dr. O’Malley and colleagues have identified a group of proteins called p160 SRCs (Steroid Receptor Cofactors) that are essential for AR activity and are associated with shorter time to disease recurrence and promote more aggressive disease. Investigators have screened roughly 400,000 compounds and identified a series of small molecule inhibitors of SRCs. They will test these compounds in prostate cancer cell lines and animal models to identify a panel of novel, first-in-class therapeutic SRC-targeting approaches to inhibit AR activity and treatment-resistant prostate cancer growth.
Bert O’Malley, MD
Baylor College of Medicine
Nancy Weigel, PhD; Ming-Jer Tsai, PhD; Francesco DeMayo, PhD; Michael Ittmann, MD, PhD; Nicholas Mitsiades, MD, PhD; Sean McGuire, MD, PhD, Baylor College of Medicine